Compare Expedia Group Inc (EXPE) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Revvity Inc — how do they compare? Expedia Group Inc trades at $274.22 (market cap $32.42B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Expedia Group Inc is the larger of the two by market cap, and Expedia Group Inc pays the higher dividend (0.71%). Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Revvity Inc for 12 Days on average.
| EXPE | RVTY | |
|---|---|---|
Market Cap | $32.42B | $16.98B |
Volume | 1,940,671 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $157.36 |
52-Week Low | $188.51 | $82.26 |
Typical Hold Time | 47 Days | 12 Days |
Enterprise Value | $30.98B | $19.30B |
Dividend Yield | 0.71% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $270.13, up 4.35% today, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.76 surpassing the $5.22 forecast. Revenue growth is steady, reaching $14.73 billion in 2025, and the company maintains a high gross profit margin of 90.43%. However, recent news highlights competitive threats from AI agents, and the stock faces resistance near $275.
The outlook for EXPE is mixed; solid earnings growth and a consensus price target of $335.06 suggest upside potential, but investor sentiment is cautious due to AI disruption risks and a nearly even split between buy and hold ratings. Key risks include Meta's Muse AI agent potentially bypassing travel aggregators and ongoing layoffs impacting operational efficiency.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
